Everest Medicines Limited (HKG:1952)

Market Cap	13.51B +10.8%
Revenue (ttm)	932.82M +103.4%
Net Income	-721.85M
EPS	-2.23
Shares Out	353.29M
PE Ratio	n/a
Forward PE	208.39
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,245,800
Average Volume	3,031,982
Open	38.30
Previous Close	38.24
Day's Range	37.88 - 39.26
52-Week Range	35.54 - 77.55
Beta	1.83
RSI	47.71
Earnings Date	Mar 30, 2026

About Everest Medicines

Everest Medicines Limited, a biopharmaceutical company, engages in the discovery, license-in, development, and commercialization of therapies and vaccines to address critical unmet medical needs in Greater China and other Asia Pacific markets. Its pipeline includes Nefecon, an oral formulation of budesonide for the treatment of immunoglobulin nephropathy (IgAN); Xerava, a fully synthetic fluorocycline intravenous antibiotic for the treatment of infections caused by susceptible gram-positive, gram-negative, and anaerobic pathogens; Taniborbactam...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2017
• Employees: 722
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 1952

Financial Performance

In 2024, Everest Medicines's revenue was 706.68 million, an increase of 461.16% compared to the previous year's 125.93 million. Losses were -1.04 billion, 23.3% more than in 2023.

Financial numbers in CNY